DSM and Swiss-based flavours and fragrances house Firmenich have agreed to merge. The deal, which is expected to close in 1H 2023, is valued at about $19.6 billion. DSM-Firmenich would have about €11.4 billion/year in sales, comparable to IFF after its combination with DuPont’s Nutrition and Biosciences business early last year.
Arxada, the former Lonza Specialty Ingredients (LSI), has agreed to merge with Troy Corporation in a move that will make a major force in antimicrobials. Private equity funds Bain Capital and Cinven, which bought LSI from Lonza in July, will be the majority owner, with Troy’s owners also investing. No further financial details were disclosed.
PharmaZell, a German-based producer of speciality APIs, and France’s CDMO Groupe Novasep are to merge under the ownership of PharmaZell’s current majority shareholder, private equity firm Bridgepoint. This remains subject to consultation with employees and other closing conditions.
The European Commission (EC) has fined Sigma-Aldrich €7.5 million for three infringements in providing incorrect or misleading information in its replies to two requests for information made pursuant to Article 11(2) of the EU Merger Regulation during the official investigation into its acquisition by Merck KGaA in 2015.
China’s State-owned Assets Supervision & Administration Commission (SASAC) has approved the long-planned merger of Sinochem and ChemChina. Partly to alleviate competition concerns, they will operate as separate subsidies of a newly created holding company owned by SASAC.
The combined entity will be by far the largest chemical producer in the world, with assets of about $245 billion. “This joint restructuring will create synergy, build up a world-class chemical company and promote a high-quality development of the chemical industry in China,” Sinochem said.